ReviewJournal of biosciences2022
Metastasis-associated protein 1: A potential driver and regulator of the hallmarks of cancer.
Review in Journal of biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- VAV2 drives glycolytic reprogramming in esophageal squamous cell carcinoma via EIF3F-mediated MTA1 deubiquitination.Cancer & metabolism · 2026Article
- Metastasis-associated protein 1 rewires prostate cancer transcriptomes via direct RNA interactions governing gene expression and alternative splicing.The Journal of international medical research · 2026Article
- From Worms to Tumors: Conserved Strategies of Cellular Arrest and Survival Governing Dormancy.Cancer research · 2025Review
- Leptin-Upregulated Metastasis-Associated Protein 1 Promotes Vasculogenic Mimicry in Breast Cancer Cells.International journal of molecular sciences · 2025Article
- Metastasis-associated protein 1: a druggable target in cancer treatment.Korean journal of clinical oncology · 2025Review
- Prenatal black carbon exposure and DNA methylation in umbilical cord blood.International journal of hygiene and environmental health · 2025Article
- Discovery of Jaspamycin from marine-derived natural product based on MTA3 to inhibit hepatocellular carcinoma progression.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis-associated protein 1 (MTA1) is an emerging transcriptional co-regulator and was found to be aberrantly expressed in different types of cancers. MTA1 has been reported to regulate multiple cancer-related signalling pathways leading to tumour progression and metastasis. Recently, MTA1 was also implicated in cancer metabolism, where it was found to regulate the 'Warburg effect' to drive breast cancer cell invasion. Overall, the functional dynamism of MTA1 can be attributed to its dual co-regulatory effects in regulating a diverse array of target genes involved in cell proliferation, DNA damage repair, angiogenesis, invasion, migration, metastasis, and metabolism in different types of cancers. In this review, we have attempted to provide a brief summary of MTA1 as a modulator of the hallmarks of cancer.
Indexed as
Identifiers
36210748W4223983650What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.